Sodium glucose co-transporter-2 (SGLT2) inhibitors. Initially meant as antidiabetic drugs, SGLT2 inhibitors are currently one of the most important pillars in the treatment of chronic heart failure (HF), these drugs being known to reduce cardiovascular outcomes, including mortality, also lowering the risk of HF-related hospitalization [48]. This evidence concerns the gene SLC5A2 and congestive heart failure.